11.55
price down icon0.86%   -0.10
after-market Dopo l'orario di chiusura: 11.90 0.35 +3.03%
loading
Precedente Chiudi:
$11.65
Aprire:
$11.45
Volume 24 ore:
403.40K
Relative Volume:
0.52
Capitalizzazione di mercato:
$620.22M
Reddito:
$8.78M
Utile/perdita netta:
$-104.70M
Rapporto P/E:
-4.8734
EPS:
-2.37
Flusso di cassa netto:
$-82.68M
1 W Prestazione:
-2.20%
1M Prestazione:
+16.55%
6M Prestazione:
+2.48%
1 anno Prestazione:
-9.98%
Intervallo 1D:
Value
$11.31
$11.86
Intervallo di 1 settimana:
Value
$11.19
$12.13
Portata 52W:
Value
$5.35
$16.15

Stoke Therapeutics Inc Stock (STOK) Company Profile

Name
Nome
Stoke Therapeutics Inc
Name
Telefono
781-430-8200
Name
Indirizzo
45 WIGGINS AVENUE, BEDFORD, MA
Name
Dipendente
128
Name
Cinguettio
@stoketx
Name
Prossima data di guadagno
2025-03-18
Name
Ultimi documenti SEC
Name
STOK's Discussions on Twitter

Confronta STOK con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
STOK
Stoke Therapeutics Inc
11.55 620.22M 8.78M -104.70M -82.68M -2.37
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-12-20 Iniziato Chardan Capital Markets Buy
2024-10-14 Ripresa Leerink Partners Outperform
2024-03-26 Aggiornamento TD Cowen Market Perform → Outperform
2023-11-20 Ripresa JP Morgan Neutral
2023-07-25 Downgrade TD Cowen Outperform → Market Perform
2023-05-01 Aggiornamento BofA Securities Underperform → Neutral
2023-04-26 Ripresa Canaccord Genuity Buy
2023-01-06 Downgrade BofA Securities Buy → Underperform
2022-10-24 Aggiornamento SVB Leerink Mkt Perform → Outperform
2022-01-31 Iniziato Jefferies Buy
2021-12-03 Iniziato BofA Securities Buy
2021-11-22 Aggiornamento JP Morgan Neutral → Overweight
2021-05-18 Iniziato UBS Neutral
2021-05-10 Aggiornamento Wedbush Neutral → Outperform
2021-04-26 Ripresa Credit Suisse Outperform
2021-02-10 Downgrade Wedbush Outperform → Neutral
2020-12-15 Ripresa H.C. Wainwright Buy
2020-12-11 Reiterato Needham Buy
2020-10-23 Iniziato Cantor Fitzgerald Overweight
2020-09-29 Ripresa JP Morgan Neutral
2020-09-29 Iniziato Needham Buy
2019-12-18 Iniziato Wedbush Outperform
2019-11-12 Iniziato BTIG Research Buy
2019-10-25 Iniziato H.C. Wainwright Buy
2019-07-15 Iniziato Canaccord Genuity Buy
2019-07-15 Iniziato Cowen Outperform
2019-07-15 Iniziato Credit Suisse Outperform
2019-07-15 Iniziato JP Morgan Overweight
Mostra tutto

Stoke Therapeutics Inc Borsa (STOK) Ultime notizie

pulisher
Jun 17, 2025

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | STOK Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Jun 17, 2025
pulisher
Jun 16, 2025

STOK FY2025 EPS Forecast Lowered by Cantor Fitzgerald - Defense World

Jun 16, 2025
pulisher
Jun 15, 2025

Stoke Therapeutics: Impressive Pipeline And Big Backers - Seeking Alpha

Jun 15, 2025
pulisher
Jun 13, 2025

Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Acquired by California State Teachers Retirement System - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

FMR LLC Increases Stake in Stoke Therapeutics Inc: A Strategic M - GuruFocus

Jun 12, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Comments on STOK FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Encephalopathy Pipeline 2025: Comprehensive Clinical Trials - openPR.com

Jun 10, 2025
pulisher
Jun 10, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Sold by Two Sigma Investments LP - Defense World

Jun 09, 2025
pulisher
Jun 08, 2025

Ameriprise Financial Inc. Has $116,000 Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World

Jun 08, 2025
pulisher
Jun 08, 2025

Jane Street Group LLC Sells 318,465 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates - mx.advfn.com

Jun 07, 2025
pulisher
Jun 07, 2025

Millennium Management LLC Increases Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World

Jun 07, 2025
pulisher
Jun 06, 2025

(STOK) Technical Data - news.stocktradersdaily.com

Jun 06, 2025
pulisher
Jun 05, 2025

Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Recommendation of “Buy” from Analysts - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

Insider Sell: Barry Ticho Sells 8,216 Shares of Stoke Therapeuti - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Insider Sell: Barry Ticho Sells 8,216 Shares of Stoke Therapeutics Inc (STOK) - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Stoke Therapeutics Adopts Key Proposals at Annual Meeting - TipRanks

Jun 04, 2025
pulisher
Jun 04, 2025

BNP Paribas Financial Markets Trims Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

ProShare Advisors LLC Acquires Shares of 12,626 Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World

Jun 03, 2025
pulisher
May 31, 2025

Contrasting Stoke Therapeutics (NASDAQ:STOK) & Renovaro (NASDAQ:RENB) - Defense World

May 31, 2025
pulisher
May 29, 2025

Stoke Therapeutics to Present at the 2025 Jefferies Global Healthcare Conference - BioSpace

May 29, 2025
pulisher
May 29, 2025

Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference | STOK Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference - Business Wire

May 29, 2025
pulisher
May 28, 2025

D. E. Shaw & Co. Inc. Sells 143,203 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World

May 28, 2025
pulisher
May 26, 2025

How to Take Advantage of moves in (STOK) - news.stocktradersdaily.com

May 26, 2025
pulisher
May 23, 2025

Northern Trust Corp Purchases 11,635 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World

May 23, 2025
pulisher
May 20, 2025

Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 28% But Its Business Still Trails The Industry - simplywall.st

May 20, 2025
pulisher
May 19, 2025

Chardan Capital Has Strong Forecast for STOK FY2025 Earnings - Defense World

May 19, 2025
pulisher
May 18, 2025

Analysts Issue Forecasts for STOK FY2026 Earnings - Defense World

May 18, 2025
pulisher
May 18, 2025

Research Analysts Issue Forecasts for STOK FY2025 Earnings - Defense World

May 18, 2025
pulisher
May 17, 2025

Wall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a Bet - MSN

May 17, 2025
pulisher
May 17, 2025

HC Wainwright Analysts Decrease Earnings Estimates for STOK - Defense World

May 17, 2025
pulisher
May 17, 2025

Q2 EPS Estimates for Stoke Therapeutics Raised by Wedbush - Defense World

May 17, 2025
pulisher
May 16, 2025

Stoke Therapeutics (NASDAQ:STOK) Stock Rating Upgraded by Cantor Fitzgerald - Defense World

May 16, 2025
pulisher
May 15, 2025

Stoke Therapeutics stock target cut to $35 by H.C. Wainwright - Investing.com Canada

May 15, 2025
pulisher
May 15, 2025

Price T Rowe Associates Inc. MD Purchases 2,215 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World

May 15, 2025
pulisher
May 14, 2025

STOK: HC Wainwright & Co. Maintains Buy Rating on Stoke Therapeu - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Stoke Therapeutics (STOK) Sees Adjusted Price Target Amid Upcoming Trial | STOK Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Stoke Therapeutics (STOK) Sees Adjusted Price Target Amid Upcomi - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Stoke Therapeutics (NASDAQ:STOK) Shares Gap Up After Better-Than-Expected Earnings - Defense World

May 14, 2025
pulisher
May 14, 2025

Stoke Therapeutics Advances with Strong Q1 2025 Results - TipRanks

May 14, 2025
pulisher
May 13, 2025

Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates | STOK Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Stoke Therapeutics (STOK) Reports Significant Q1 Revenue Growth - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance

May 13, 2025
pulisher
May 13, 2025

Stoke Therapeutics Provides Business Updates - citybiz

May 13, 2025
pulisher
May 13, 2025

Stoke Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 13, 2025
pulisher
May 13, 2025

Stoke Therapeutics Inc (STOK) Reports Q1 2025 Earnings: EPS of $ - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Stoke Therapeutics Q1 Operating Income USD 111.24 Million - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Stoke Therapeutics Inc (STOK) Reports Q1 2025 Earnings: EPS of $1.90 and Revenue of $158.6 Million, Surpassing Estimates - GuruFocus

May 13, 2025

Stoke Therapeutics Inc Azioni (STOK) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Stoke Therapeutics Inc Azioni (STOK) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Ticho Barry
CHIEF MEDICAL OFFICER
Jun 03 '25
Sale
10.03
6,471
64,892
25,782
Ticho Barry
CHIEF MEDICAL OFFICER
Jun 02 '25
Sale
10.00
1,745
17,450
32,253
Ticho Barry
CHIEF MEDICAL OFFICER
May 02 '25
Sale
10.03
22,790
228,543
33,998
Ticho Barry
CHIEF MEDICAL OFFICER
May 01 '25
Sale
10.00
3,841
38,410
56,788
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Capitalizzazione:     |  Volume (24 ore):